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1. Introduction 
Alzheimer’s disease (AD) is a neurological disorder characterized by profound memory loss 
and progressive dementia. The pathological and histological hallmarks of AD include 
amyloid plaques, neurofibrillary tangles and amyloidal angiopathy, accompanied by diffuse 
loss of neurons and synapses [1]. Environmental and genetic factors  interact  in the 
development of disease. Type 2 diabetes mellitus (DM) appears to be a significant risk factor 
for vascular dementia and AD in several epidemiological studies [2, 3]. Recent longitudinal 
studies have shown that AD and disorder of glucose metabolism are related [4, 5]. One 
explanation could be that vascular complications of diabetes result in neurodegenerative 
disease [6]. On the other hand, in addition to its peripheral metabolic effects, insulin also 
appears have important outcome on brain functions. A recent commentary offers two 
models of the link between type-2 DM and AD, 1. “central insulin resistance” and 2. 
inflammation. Both mechanisms influence insulin sensitivity in the brain, finally leading to 
┚-amyloid accumulation and, consequently, to AD [7]. Complex molecular mechanisms, 
referring to insulin and/or insulin like growth factor-1 (IGF-1) signaling could link DM and 
AD [8]. In fact, there is evidence that altered insulin and/or IGF-1 signaling to brain cells is 
probably responsible of amyloid accumulation in AD [9] and several independent effects of 
insulin on brain functions and cognitive performance have been described [10]. Insulin 
resistance with associated hyperinsulinemia are the mechanisms suggested to explain the 
increased AD risk in diabetes [11]. Subsequent investigations demonstrated reduced blood 
glucose levels and increased insulin levels in patients with late onset AD compared to aged 
controls or patients with vascular dementia. Although the authors concluded that these 
findings did not support an association between diabetes and AD [12], the same data were 
reinterpreted as an increased prevalence of insulin resistance in AD. The latter conclusion 
contradicts the finding that glucose administration could both increase plasma insulin levels 
and improve cognition in AD. Working under the assumption that increased insulin rather 
than glucose was responsible for the improvement in memory, further studies were used to 
demonstrate that the administration of insulin significantly improved memory performance 
in AD [8, 13]. Hyperinsulinemic euglycemic clamp studies in humans showed improvement 
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of attention in AD patients  and neuroelectric changes in evoked potential induced by 
insulin [14]. In contrast, increases in plasma glucose that were not accompanied by increases 
in insulin levels did not influence cognitive performances [15]. The Rotterdam Study was 
one of the first epidemiology surveys to provide convincing evidence on a relationship 
between DM and dementia based on a significantly higher prevalence of dementia in 
patients with insulin-dependent (Type 1) DM compared to non diabetic aged controls [3]. In 
addition, the possible association between DM-insulin resistance and degree of 
hippocampal and amygdala atrophy was investigated in vivo by magnetic resonance 
imaging [16]. The study showed that: 1. Individuals with DM had greater degree of 
hippocampal and amygdala atrophy compared with subjects who did not have DM; 2. 
Severity of insulin resistance associated with degree of amygdala atrophy. The inability to 
convincingly demonstrate a correlation between DM and AD, or find evidence that DM 
causes neuropathology, led to the alternative hypothesis that diabetes may serve as a co-
factor in the pathogenesis of dementia and possibly AD. In this regard, epidemiological 
studies showed that hyperinsulinemia in patients with APO E4-negative genotype was 
correlated with AD-type dementia, whereas in the absence of diabetes, APO E 4+ genotype 
was also correlated with AD [17], suggesting that APO E4 genotype and DM contribute 
independently to the pathogenesis of AD. Correspondingly, post-mortem studies have 
shown that individuals with DM and APO E4 genotype had significantly more abundant A┚ 
deposits and neurofibrillary tangles compared with diabetics who did not have an APO E4 
allele [18]. In this review, we will summarize current evidences supporting the association 
between insulin action, insulin receptors, IGF-1 and AD, and we will describe the  
underlying mechanisms. 
2. Insulin, IGF-1: Secretion, transport and distribution in human brain 
Insulin is almost exclusively synthesized and secreted into the plasma by pancreatic ┚-cells 
and has important role in metabolic homeostasis. Although accumulated evidence indicate 
that insulin is derived from peripheral insulin and transferred by a transporter regulated 
way through the blood-brain-barrier (BBB), [19, 20] there is also evidence consistent with 
local synthesis of insulin in the brain. In fact, Schechter et al. demonstrated that insulin can 
be produced locally in rabbit neuronal cells from culture [21]. besides, Devaskar et al. 
revealed localization of insulin expressing neurons involved in associative areas of limbic 
system and areas regulating olfaction [22]. On the other hand, it is now generally thought 
that insulin synthesis in the brain is restricted is not synthesized to any significant amount 
in adult developed brain [20]. Over the past few years, it has become clear that insulin and 
IGF-1 also have intense effects in the central nervous system (CNS), regulating key processes 
such as energy homeostasis, neuronal survival, longevity, as well as learning and memory. 
Insulin and IGF-1 bind to tyrosine kinase receptors, the insulin receptor (IR) and IGF-1 
receptor (IGF-1R), which share a high degree of identity in their structure and function. 
Insulin and IR are abundant but selectively distributed in the brain. Rodent studies have 
shown that insulin binding is highest in the olfactory bulb, cerebral cortex, hippocampus, 
hypothalamus, amygdala and septum [23, 24]. In the adult mammalian brain, two types of 
IR were found: a peripheral type and a neuron-specific type [25]. Insulin signaling within 
the cell is mediated, in general, by two functional cascades, one acting through the 
phosphatidylinositol-3 (PI3) kinase pathway, and other acting through the mitogen-
activated protein kinase pathway [26]. Binding of insulin or IGF-1 induces a conformational 
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change of the receptor and activates tyrosine-kinase which leads to auto-phosphorylation of 
the intracellular ┚-subunit [27]. Tyrosine-phosphorylate IR and IGF-1R ┚-subunits recruit 
and subsequently phosphorylate tyrosine residues of the intracellular insulin receptor 
substrates (IRS). The IRS protein family has at least four members, IRS-1 to -4 [28]. IRS 
proteins are homologue in structure and function but show distinct tissue distribution: IRS-1 
and IRS-2 are widely distributed throughout different tissues and the brain, whereas IRS-3 is 
only expressed in rodent adipose tissue, and IRS-4 is predominantly localized in 
hypothalamus, thymus, skeletal muscle, heart, kidney, and liver [29]. IR and IGF-1R are also 
expressed on brain capillaries and mediate the high efficiency translocation of insulin and 
IGF-1 into the brain across the BBB [30, 31]. Several studies have shown the highest IR 
density in olfactory bulb, hippocampal formation, hypothalamus, and cerebral cortex [32, 
33]. In fact, in postmortem studies in adult humans, Adem et al. showed the highest IGF-1R 
density in hippocampus, amygdala and parahippocampal gyrus [33]. Whereas the density 
of brain IR decreases during age, IGF-1R increases, suggesting that specific insulin mediated 
signals are involved in aging and possibly cause age associated cognitive decline [34, 35]. 
Insulin has been shown to cross the BBB by different mechanisms: extracellular pathways, 
non-saturable transmembrane diffusion or saturable active transport [36]. Currently, the 
majority of studies suggests that the largest proportion of insulin crosses the BBB by 
receptor-mediated transport [37]. In contrast, insulin IGF-1 is formed within the CNS during 
the development and, to a lesser extent, in the mature brain [38]. However, Rotwein 
suggests that IGF-1 might cross the BBB via an analogous mechanism like insulin [39]. 
3. Insulin and IGF-1 signaling in Alzheimer’s disease 
In normal physiology, insulin facilitates memory as demonstrated when administration at 
optimal doses and in contrast of sufficient glucose availability [15]. Type-2-diabetic patients 
are insulin resistant and have chronic hyperinsulinemia. The peripheral utilization of insulin 
reduces insulin transport into the brain, ultimately producing brain insulin deficiency [40], 
and abrogating the beneficial influences of insulin on the brain functions [15]. Different 
insulin levels have been observed in different brain regions [30, 41], probably linked to 
multiple insulin actions in CNS. Studies on type-2-DM animal models have shown a 
reduced uptake of insulin into the brain. It was observed that obese diabetic Zucker rats 
have a decreased insulin transport into the brain, reduced brain levels of insulin and 
peripheral hyperglycemia [30, 36, 41]. Recent studies linked diabetes with AD [8, 9, 18] and 
suggested that the brain may be influenced by changes in insulin levels and sensitivity. The 
observations that insulin, insulin receptors and C-peptide levels in cerebrospinal fluid (CSF) 
appears to be reduced in aging [42], along with the finding that AD patients have lower 
levels of insulin in the CSF, suggest impaired transport of insulin into the brain [43]. 
However the salutary effect of insulin on brain functions are reserved under conditions that 
impair its functioning, such as insulin resistance [44]. Frolich et al. found that neuronal 
tyrosine-kinase activity is decreased in AD patients compared to age-matched controls [35]. 
The overall expression of IGF-1R is reduced in AD brains dependent on the severity of the 
disease. Brain IGF-1 mRNA levels diminish in severe AD, whereas IGF-1 serum levels are 
increased in early stages of the disease, suggesting that IGF-1 resistance plays a role in the 
pathogenesis of AD [35]. IRS-1/2 protein expression is reduced in AD brains, and 
inactivating Serine-phosphorylation of IRS-312 and Ser616 is improved, leading to impaired 
insulin resistance and IGF-1R signaling [45]. Given that IRS are widely expressed in the 
hippocampus, the most studied brain region for learning and memory, it seems to be 
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plausible that decline of insulin resistance signaling leads to cognitive impairment [46]. 
Experiments with adult mice lacking liver IGF-1 production with an up of 85% reduction in 
circulating IGF-1 showed impaired spatial memory in the Morris water maze task compared 
to wild type litter mates [46]. These findings might explain the reduction of cognitive 
functions during aging, since IGF-1 serum levels diminish under physiological conditions 
[47]. Unpredictably, studies in neuronal-IR-knockout mice (NIRKO) did not provide 
evidence for impairment in learning and memory, proposing that insulin resistance alone is 
not a key feature in dementia and neurodegeneration [17]. 
3.1 Glucose metabolism and Alzheimer’s disease 
Some of the earliest work on senile dementia, which probably corresponded to AD, vascular 
dementia, or a combination of both, documented the development of altered brain 
metabolism soon after the onset of clinical symptoms [48, 49]. The metabolic abnormalities 
consisted of impaired glucose utilization and energy metabolism, with features that 
resemble type-2 DM [48]. In addition, several studies confirmed that cerebral metabolism 
declined prior to the deterioration of cognitive functions, suggesting that energy failure is 
one of the earliest reversible hallmarks of AD. These observations led to the hypothesis that 
AD-associated abnormalities in energy metabolism are caused by IR action in the brain, i.e. 
brain diabetes [49].  
3.2 Insulin therapy and Alzheimer’s disease 
There are conflicting findings regarding the effects of antidiabetic therapy on clinical and 
neuropathology of AD. The  Honolulu-Asia Aging Study demonstrated improvement of 
cognitive function and memory following induced hyperinsulinemia in patients with AD 
[2]. Conversely, the Rotterdam Study [3] observed increased risk of dementia in subjects 
with diabetes treated with insulin. In fact, in this prospective study, DM almost doubled the 
risk of dementia [Relative Risk (RR) 1.9] and patients treated with insulin were at higher risk 
of dementia [RR 4.3]. In opposition, recent studies suggest that the combination of insulinic 
therapy with other diabetes medications is associated to a lower neuritic plaques [50] and to 
slower cognitive decline in patients with AD [13]. Besides, studies in animals  have revealed  
the beneficial effects of peripheral and cerebroventricular injections of insulin on memory 
and learning [51]. Several studies have recognized that increasing plasma glucose levels 
improves memory in patients with AD [14, 15, 30]. Increasing plasma glucose levels also 
increases endogenous insulin levels, raising the query whether memory improvement is due 
to changes in insulin, independently of hyperglycemia [14], although the exact mechanism 
remains unclear. Dense IR distributions have been documented in the dentate gyros, CA1, 
and CA3 fields of the hippocampus [52]. These regions are known to play a role in 
declarative memory and they are affected earlier and most severely by the neuropathologic 
changes of AD [53]. Increased plasma insulin levels result in amplified insulin binding in 
hippocampus. In turn, increased brain insulin levels results in enlarged glucose utilization 
in the entorhinal cortex [54]. In contrast to the traditional notion that the brain is not an 
insulin-sensitive organ, insulin-promoted glucose utilization also results in glycolytic 
production of acetyl-CoA and subsequent increase in acetylcholine [55], a neurotransmitter 
closely linked to memory function and severely reduced in AD. Craft et al. confirm that 
elevated insulin without hyperglycaemia enhances memory in adults with AD, when 
endogenous insulin was suppressed by concomitant infusion of somatostatin analogues 
[14]. Moreover, the beneficial effect of insulin appears to be reduced when insulin resistance 
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is present [17]. Craft et al. showed acute effect of hyperinsulinemia in older adults and in 
patients with AD using a hyperinsulinemic-euglycemic clamps [15]. Low doses of insulin 
improve memory in normal subjects; AD patients with insulin resistance required higher 
insulin doses to obtain memory improvement. To date, no genetic risk factors have been 
identified for these patients, raising the possibility that factors relating to insulin resistance 
may be important for AD pathogenesis [15]. 
3.3 Insulin and oxidative stress mechanisms in Alzheimer’s disease 
Insulin promotes cell membrane expression of N-methyl-D-aspartate (NMDA) receptors, 
with increased neuronal Ca2+ influx [56]. Ca2+ influx presumably activates Ca2+dependent 
enzymes, including ┙-dependent enzymes and strengthens neuronal synaptic association 
[10]. A recent study identified a molecular mechanism that protects CNS neurons against ┚-
amyloid-derived-diffusible ligands (ADDL), responsible for synaptic deterioration 
underlying AD memory failure. The authors found ADDL binding to particular synaptic 
sites, and the resulting oxidative stress on synapses loss are markedly decreased by the 
presence of insulin. The protection mechanism does not involve simple competition 
between ADDLs and insulin, but rather is signaling-dependent down regulation of ADDL 
binding sites [57]. Another metabolic disturbance of emerging importance in AD involves 
insulin signaling in the brain. Levels of insulin receptors, glucose-transport proteins, and 
other insulin pathway components are reduced in some studies of AD brain (central 
resistance) [30]. Han et al. proposed a central insulin resistance together with decreased 
brain insulin levels might lead to accumulation of ┚-amyloid and consequently AD [7]. 
Insulin and brain derived IGF-1 instigate signals in the brain by activating the 
phosphatidylinositol-3-kinase-Akt pathway and the mitogen-activated protein kinase-
extracellular signal-regulated kinase pathway [58], but it is unclear whether signaling is up-
regulated (compensatory) or down-regulated (pathologic) in AD. Aging and life span are 
also influenced by insulin. Both in AD and in normal aging process mtDNA sustains high 
levels of oxidative damage (Figure 1) [59]. In fact, it was observed the accumulation of A┚ 
within structural damaged mitochondria isolated from the brains of AD patients [59, 60] and 
transgenic brains [61], which impair critical mitochondrial enzymes. Dysfunctional 
mitochondria release oxidizing free radicals, with peroxidation of membrane lipids and 
output of toxic aldehydes that cause considerable oxidative stress in AD and in normal 
aging brains [62]. Other essential proteins resulted oxidized, yielding carbonyl and nitrated 
derivatives, in neuronal cytoplasm in cerebral regions of neurodegeneration, in human brain 
affected by AD [63]. Subsequently, increased membrane permeability to calcium, and 
impaired glucose transport aggravate the energy imbalance [64]. Experimental model show 
that markers of oxidative damage precede pathological changes [65]. Destruction of 
mitochondria by the oxidation of a dynamic like transporter protein may cause synapse loss 
in AD [66]. The “receptor for advanced glycation end products” (RAGE) mediates A┚'s pro-
oxidant effects on neural, microglial, and cerebrovascular cells [67]. The RAGE receptor is a 
multi-ligand receptor, and one of its ligands is A┚ [67]. RAGE regulates several intracellular 
pathways [68], such stimulates expression of b-site Amyloid Precursor Protein (APP)-
cleaving enzyme 1 (BACE1) [69], an enzyme that is necessary for A┚ production. Moreover 
RAGE seems to negatively affect the  long term potentiation (LTP) synaptic process of 
learning and memory [70]. RAGE also exists in a soluble form, structured by alternative 
splicing [71] or proteolytic cleavage by the metalloprotease 10 (ADAM 10) [72]. Soluble 
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RAGE (sRAGE) contains the ligand-binding site, but does not have the signaling properties 
of full-length RAGE (flRAGE). It was observed that flRAGE is engaged in positive feedback 
mechanisms, enhancing its own production, and limiting sRAGE proposed protective 
actions. This notion is supported by the finding that flRAGE expression is increased in AD 
brains [73]. Indeed, studies have shown that sRAGE can inhibit the accumulation and 
aggregation of A┚ in mice brains [74]. In addition, it has been shown that sRAGE is present 
at lower levels in the blood and brain of AD patients [75]. Abnormal expression of RAGE in 
AD brain suggests that it is relevant to the pathogenesis of neuronal dysfunction and death. 
 
Fig. 1. Oxidative distress 
Dysfunctional mitochondria release oxidizing free radicals, and in Alzheimer’s disease 
(AD), they cause significant oxidative stress. Oxidative damage precede pathological 
changes. A┚, a strong generator of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), is a prime author of this damage. The receptor for advanced glycation end 
products (RAGE) mediates A┚’s pro-oxidant effects on neural, microglial and 
cerebrovascular cells. Mitochondrial hydrogen peroxide readily diffuses into the cytosol to 
contribute in metal-ion-catalyzed hydroxyl radical development. Moved microglia are a 
major source of the highly diffusible nitric oxide radical. These reactive oxygen species and 
reactive nitrogen species damage several molecular targets. Peroxidation of membrane 
lipids yields toxic aldehydes, which impair critical mitochondrial enzymes. Other essential 
proteins are directly oxidized, yielding carbonyl and nitrated derivates. Consequently, 
increases in membrane permeability to calcium, other ionic imbalances, and impaired 
glucose transportation worsen the energy imbalance.   
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4. The insulin and IGF-1R signaling and Tau phosphorylation 
Soluble tau proteins assemble with tubulin to constitute cross bridge between adjacent 
microtubule and promote stability of microtubules and vesicle transport [76]. 
Hyperphosphorylation of tau induces abnormal insoluble tau protein [77]. Neurofibrillary 
tangles are hyperphosphorilated, intracellular polymers of tau proteins. Neurofibrillary 
tangles are intracellular polymers of tau proteins, observed in cytoplasm of neurons [76] in 
AD and  in other neurodegenerative disorders, such as frontotemporal dementia, Pick’s 
disease, corticobasal degeneration, supranuclear palsy. Several studies [78, 79] supposed 
that the interaction between A┚ and tau proteins is necessary to cause neuronal loss.  When 
hyperphosphorylated, tau aggregates and interferes with intraneuronal metabolism and 
transport, leading to neurodegeneration. IR/IGF1 R mediated might be involved in 
regulation of tau phosphorilation, amyloid precursor protein cleavage, ┚ amyloid transport 
and degradation, in memory and aging [8]. The phosphorilation of tau is mainly promoted 
by glycogen syntase kinase (GSK)3┚ and cyclin dependent kinase(Cdk5).GSK3┚ is a serine-
treonine kinase,regulated by insulin/IGF-1 signaling pathway. GSK-3┚ is functionally main 
for regulating glycogen metabolism, proliferation survival, and cell migration [77]. When 
the IR/IGF-1cascade is activated, GSK┚ is phoshorilated by protein kinase AKT at serin 
leading  to its inactivation [80-82] (Figure 2). PP2A dephosphorylates tau maintaining an 
equilibrium of phosphorylation and dephosphorilation of tau [82, 83]. Protein phosphatases 
2A (PP2A) is the major phosphatases with 70% activity in human brains [84]. This implies a 
protective role of PP2A in neurodegeneration which is consistent with the finding that PP2A 
activity is reduced in AD brains [85]. In vitro studies it was found   that insulin influences a 
regulatory interaction between PP2A and GSK 3┚, inducing in activity of both enzymes 
change in the same direction. This balanced response seemed to preserve equilibrated tau 
phosphorilation [86, 87]. Several studies  on different animal models  of insulin resistance 
showed  that impaired IR /IGF-1 signaling  and hyperinsulinemia increased tau 
phosphorylation.[88-89]. In streptozotocina treated mice, model of type 1 diabetes, 
hyperphosphorilation of tau has be shown, which was reversible after peripheral insulin 
treatment [90]. Another important physiological role of insulin and IGF-1  in the brain is the 
regulation of gene transcription by MAP kinase cascade. This pathway  leads to activation of  
extracellular signal-regulated kinase (ERK)-1/-2, involved in long lasting neuronal 
plasticity, memory consolidation and apoptotic neuronal death [91-93]. Thus, altered 
IR/IGF-1 signaling  as well as lack of insulin might lead to hyperphosphorylation of tau 
protein and an increased formation of neurofibrillary tangles. These findings suggest that 
hyperphosphorylation of tau follows an imbalance of insulin regulated tau kinases and 
phosphatases [94].  
Protein  phosporylation/dephosphorylation imbalance is generate, at least in part, by a 
decrease in the activities of tau phosphatases (PP2A), and increase the activities of tau 
kinase (i.e. cdk5, GSK-3, etc.) affected by insulin. Impaired insulin signaling stimulates GSK-
3┚ activity that increases oxidative stress and tau hyper-phosphorylation, by Cdk-5. Severe 
or sustained oxidative injury leads to mithocondrial DNA damage, mithocondrial 
dysfunction, apoptosis and the attendant cell loss and impaired neuronal function lead to 
dementia. Age reduces membrane fluidity inducing mutations in transmembrane proteins, 
(i.e. PS1, PS2,..), and vulnerability of the cell membrane to variation in pathological signal 
transduction.  
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Fig. 2. Dementia and anomalous hyperphosphorylation of tau  
4.1 Protein phosphatases A (PPA) processing in Alzheimer's disease 
The amyloid plaques is formed by amyloid ┚ (A┚) peptides organized in fibrils intermixed 
with non fibrillar forms of this peptide and are surrounded by dystrophic dendrites, axons, 
reactive astrocytes and activated microglia. A┚ consists of small hydrophobic peptides with 
N- and C-terminal heterogeneity, i.e. A┚1-40 and A┚1-42 which are proteolytically released 
from a large type 1 integral membrane glycoprotein, the APP, via sequential cleavage by 
two aspartyl proteases, the ┚- and ┛-secretases [enzymatic complex, containing nicastrina, 
presenilina, preselin enhancer-2 (PEN-2), CD147] [95]. Initial ┚-secretase cleavage generates a 
soluble fragment from the NH2-terminus of APP, while the c-terminal fragment (┚-CTF) 
stays membrane bound. Full-length APP can undergo alternative processing by ┙-secretase, 
generating a soluble APPs┙ ectodomain and a membrane-bound carboxy-terminal 
fragment, APP-CTF┙. Processing of APP by ┙-secretase is postulated to be protective in the 
context of AD, because the enzyme cleaves within the A┚-sequence, thereby preventing the 
production of A┚. APP, ┙CTF and ┚CTF are further cleaved by ┛-secretase to generate p83 
fragment and A┚ respectively [96]. Multiple lines of biochemical evidence have shown ┛-
secretases activity to reside in a high molecular weight complex, consisting of at least four 
components: presenilin (PS, PS1, PS2), nicastrin, anterior pharynx-defective (APH-1) and 
PEN-2 [97]. The p83 fragment is rapidly degraded and widely believed to possess no 
important function, if any. ┛-secretase-mediated cleavage is unique in that the cleavage 
takes place within the membrane domain, though the exact site can vary. ┛-cleavage can 
yield both A┚1-40 and to a lesser extent A┚1-42 [96]. A┚ are toxic, and their accumulation is 
Β-secretase
γ-secretase
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currently seen as a key step in the pathogenesis of AD (Figure 3). Closer examination of the 
amyloidogenic ┚- and ┛-secretates discovered the membrane-anchored aspartyl protease ┚-
site BACE-1, which acts as ┚-secretase and presenelin 1-2, transmembrane proteins involved 
in formation of the ┛-secretase complex, as the responsible cleavage enzymes. Thus, 
alteration of their activity might be a possible target for AD treatment [98]. It has been 
shown that BACE-1 levels are increased in post-mortem brain sections from AD patients 
[99]. During aging changes in the cerebral expression levels of the neurotrophin receptors, 
TrkA (tyrosine kinase receptor A) and p75NTR (p75 neurotrophin receptor) have been 
described. In the human neuroblastoma cell line SHSY5Y as well as primary cultured 
neurons, chronic treatment with IGF-1 leads to a switch from TrkA to p75NTR expression as 
seen in aging brains [100]. This switch causes increased ┚-secretase activity indirectly by 
activation of neuronal sphingomyelinase which is responsible for hydrolysis of 
sphingomyelin and active liberation of the second messenger ceramide [101]. Ceramide is 
responsible for the molecular stabilization of BACE-1, the ┚-secretase which is rate-limiting 
for generation of A┚ [102]. This process leads to accumulation of A┚, connecting IGF-1R 
signaling to neurotrophin action. These data might provide a molecular link between aging, 
pathogenesis of AD and neuronal insulin-IGF-1 signaling. Lots of research has been done on 
the formation and accumulation of A┚, however, in the last years the mechanisms of 
amyloid clearance came into focus.  
 
 
Fig. 3. Amyloid placque formation. 
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The histological and pathological features of AD are amyloid plaques, neurofibrillary 
tangles and amyloid angiopathy. The dominant component of the placque core is the the 
amyloid beta-peptide (A┚) organized in fibrils of approximately 7-10 nm intermidex with 
non  fibrillar forms of this peptide. A┚ is a a 39-43 aminoacid peptide proteolytically 
released from a much larger precursor, tha amyloid precursor protein (APP). The generation 
of A┚ from APP requires the sequential recruitment of two enzymatic activities: ┚-secretase, 
also called BACE1 (for beta side APP cleaving enzyme), and ┛-secretase , a multicentric 
protein complex containing presenelin, nicastrina,..A┚ spontaneously self-aggregates into 
multiple coexisting physical forms, such as oligomers (2 to 6 peptides), transitional 
assemblies, fibrils  that coalesce into ┚ pleated sheets to form insoluble fibers and amyloid 
plaques. While monomeric A┚ is not neurotoxic, the A┚ oligomers exhibits a marked 
toxicity (Adapte from Martin JB; 1999).   
4.2 Insulin, IGF-1 signaling and β-amyloid in Alzheimer’s disease 
┚-amyloid spontaneously self-aggregates into multiple coexisting physical forms, such as 
oligomers (2 to 6 peptides), intermediate assemblies, fibrils  that coalesce into ┚ pleated 
sheets to form insoluble fibers and amyloid plaques [103]. While monomeric A┚ is not 
neurotoxic, the A┚ oligomers exhibits a marked toxicity [104]. Neuronal activation rapidly 
increase A┚ secretion at the synapse, during the  process of neurotransmitters release. 
Normal levels of A┚ at this site may modulate neuronal transmission and prevent 
hyperactivity [105]. It was assumed that imbalance between production, aggregation and 
clearance of peptides, is considered initiating factor in AD [106]. For A┚ clearance several 
mechanisms have been described: 1. enzymatic degradation by activated microglia or by 
insulin degrading enzyme (IDE), neprilysin, endothelin converting enzyme (ECE), and 
angiotensin converting enzyme (ACE); 2. receptor-mediated transport across the BBB by 
binding to the low-density lipoprotein receptor-related protein (LRP), either directly or after 
binding to APO E and/or ┙2-macroglobulin (┙2M), to be delivered to peripheral sites of 
degradation, e.g., liver and kidney [41]. Concerning insulin resistance it has been shown that 
IDE expression is stimulated by the insulin resistance-IGF-1R cascade [107]. It has been 
recently reported that membrane associated G protein-coupled receptor kinase-5 (GRK5) 
deficiency occurs during early AD [108]. In deficient GRK5 mice (tg2576-APPsw) Aß 
accumulation resulted significantly increased [108]. IGF-1 administration resulted in 
reduction of cerebral A┚ load in these mice, whereas A┚ was elevated in CSF suggesting an 
increased A┚ elimination across the BBB or the choroid plexus [109]. Furthermore, it has 
been shown that the blockade of the IGF-1R in the choroid plexus triggers AD-like 
pathology. Furthermore, tau phosphorylation did not change significantly following chronic 
IGF-1 treatment in Tg2576 mice [109]. A possible explanation could be that the chronic 
increase of IGF-1 by peripheral treatment might down regulate IGF-1R signaling. This 
hypothesis is supported by the finding that in a cohort of individuals with exceptional 
longevity serum IGF-1 levels were high but IGF-1R activity was low leading to reduced IGF-
1R signaling [110]. However, induction of insulin resistance by high fat diet [111] or intake 
of sucrose-sweetened water [112] leads to an aggravation of amyloid pathology in mouse 
models of AD. Furthermore, peripheral injection of supra physiologically high insulin doses 
but not of physiological doses leads to transient cerebral tau phosphorylation [113], leading 
to the proposal that there is a dose dependent effect of insulin resistance-IGF-1R signaling in 
the pathogenesis of AD.  
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5. Insulin, inflammation and Alzheimer's disease 
In recent years inflammatory pathway  have been linked to type 2 diabetes mellitus, 
metabolic syndrome (MS) and neurodegenerative diseases, including AD. Inflammation as 
able to accelerates the development type2 DM, through its influence on peripheral insulin 
sensitivity and pancreatic islet function; on the other hand, in addition to impaired insulin 
signaling, diabetes accelerated the appearance of cerebrovascular inflammation and A┚ 
deposition, as evidenced by increased levels of proinflammatory cytokines IL6 and TNF┙, as 
well as dense amyloid deposits in blood vessels.  [7, 114]. Cerebrovascular and central 
inflammation, along with increased accumulation of ┚ amyloid, disrupts normal synaptic 
function, a starting point of AD progression. It was hypothesized the mutual interaction 
between AD and DM. Takaeda observed increased severity of diabetic phenotype in  AD 
animal  models. The reciprocal actions between AD and type-2 DM thus form a vicious 
cycle, further illustrating the possibility that AD and type-2 DM may share common cellular 
and molecular  mechanisms [114] (Figure 4). Peripheral and central inflammation might  
affect pathogenesis of DM and AD. Elevated concentrations of interleukin (IL) 6 E2–
isoprostane have been observed in CFS of patients with AD [115]. Furthermore, in vitro and 
animal studies suggest that inflammation interacts with processing and deposit of A┚ [116]. 
Insulin exerts multiple effects involved in inflammation. In peripheral tissues insulin 
modulates many aspects of inflammatory network. Low doses of insulin exert anti-
inflammatory effects [117]; however, during chronic hyperinsulinemia, insulin may 
exacerbate inflammatory responses and increase markers of oxidative stress [118]. In 
human, co-administration of insulin and lipopolysaccharide produces a synergist increase in 
plasma concentrations of C-reactive protein and proinflammatory cytokines IL-1┚, IL-6, 
TNF┙ [119]. TNF┙ has both neurotoxic and neuroprotective effects mediated respectively by 
two receptor subtypes, TNF-R1 and TNF-R2. TNF-R1 contains a death receptor domain, and 
has been implicated in pro-apoptotic events, whereas TNF-R2 promotes cell survival. 
Increased levels of TNF-R1 and decreased levels of TNF-R2 have been observed in AD brain  
[120]. Abnormal levels of soluble TNF-R1 and R2 have been documented in adults with 
diabetes and impaired glucose tolerance [121], which reportedly normalize after a 3-weeks 
low calorie diet [122]. Insulin may also modulate levels of eicosanoids such as F2-
isoprostane via regulation of prostaglandin production in adypocites [123]. For example, 
elevated eicosanoid concentrations have been observed in hyperisulinemic Zucker rats [41]. 
Furthermore, excessive or chronic hyperinsulinemia inhibits degradation of protein 
damaged by oxidation and leads to formation of superoxide anions [124]. Insulin may also 
contribute to inflammation in the CNS, partially through effects on A┚. In fact, A┚42 interacts 
with inflammatory agents in a cyclically reinforcing manner, such that  A┚ elevations 
increase pro-inflammatory cytokines [125]. In vitro, soluble  A┚ oligomers rapidly increase 
IL-1┚ and TNF┙ levels [126]. Conversely, IL-6 and IL-1┚ can regulate processing of the APP 
from which A┚ is derived and increase production of A┚42 [127]. The mutually reinforcing 
effects of A┚, TNF┙, IL-1┚ and IL-6 may thus create a “cytokine cycle” [125]. In the 
periphery, insulin reduces hepatic production of Apo E and regulates its uptake by low-
density lipoprotein receptor-related protein [128]. Fishel et al. showed that insulin reduced 
plasma Apo E levels, an effect that increased with age. In contrast, insulin increased CSF 
Apo E concentrations for older subjects [129]. Increased brain APO E levels have been 
reported in AD in association with polymorphisms in the promoter region of the APO E 
gene that influence protein expression [130]. Recent studies showed that insulin-induced 
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elevations of CSF APO E levels were associated with attenuated increase IL6 and TNF┙ 
levels and with higher anti-inflammatory cytokine, IL-1┙ concentration. This pattern 
suggests multiple insulin effects that modulate the  role of APO E in response to 
inflammation in CNS [129] .Insulin can regulate CNS norepinephrine [131], an endogenous 
anti-inflammatory neuromodulator that blocks IL-1┚ expression [132].  Increased A┚ plaque 
load in AD has been linked to neuronal loss in the locus coeruleus, the primary source of 
brain norepinephrine [133].  In human,  raising plasma insulin levels while maintain 
euglycemia increases CSF norepinephine levels [134].Thus, these findings support the 
notion that insulin action is involved in neutrasmitter modulation and insulin abnormalities 
might  contribute to CNS inflammation. 
 
 
Fig. 4. The underlying link between Alzheimer’s disease (AD) and type-2 Diabetes Mellitus 
(DM). 
Inflammation influences islet function and peripheral insulin sensitivity. Besides, 
inflammation accelerates the development of type-2 DM. Cerebrovascular and central 
inflammation, along with increased accumulation of ┚-amyloid, disrupts normal synaptic 
function, a starting point of AD pathological progression. 
6. Conclusion 
Mild to moderate impairments of cognitive functioning has been reported both in patients 
with DM-type1 and in patients with DM-type2. The potential impact of DM on cognitive 
functions in the elderly is further emphasized by several large epidemiological surveys that 
report an increased incidence of dementia among DM patients. Several mechanisms may be 
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involved in accelerated cognitive decline in patients with DM. Insulin may affect the 
metabolism of Aβ and tau, two proteins that represent the building blocks of amyloid 
plaques and neurofibrillary tangles, the neuropathological hallmarks of AD. Moreover, 
insulin and its receptor are widely distributed throughout the brain, with particular 
abundance in defined areas, such as the hypothalamus and the hippocampus. In addition, 
insulin appears to act as "neuromodulator", that influences the release and reuptake of 
neurotransmitters, and improves learning and memory. These findings could provide 
insights to develop a strategy for prevention and treatment of AD. Insulin therapy plays an 
important role in cognitive processes and could slow dementia in patients with AD and DM. 
This could be explained by: 1.molecular mechanisms, insulin promotes cell membrane 
expression of NMDA receptors, which increases neuronal Ca2+ influx [56], that activates 
Ca2+-dependent enzymes, including ┙-dependent enzymes and strengthens neuronal 
synaptic association [10]; 2. glucose metabolism, low concentrations of exogenous insulin may 
increase cerebral glucose metabolism and then modulate brain functions such as memory 
[135]. In fact, insulin has shown a significant effect on global brain glucose metabolism and 
this effect is mainly expressed in the cerebral cortex; 3. neurotransmitter modulation, low 
doses of insulin can reverse the amnestic effects of cholinergic blockade  [136]. Although the 
concepts of "Cerebral Insulin Resistance" and "insulin-induced amyloid pathology" are an 
attractive explanation for some of the effects of DM2 on the brain, there are still many loose 
ends. It is important to point out that definitive conclusions about the value of insulinic 
treatment in course of AD cannot be established at this time.  
 
 
Fig. 5. Schematic representation of molecular mechanism, glucose metabolism and 
neurotransmitter modulation 
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Insulin promotes cell membrane expression of NMDA receptors, which increases neuronal 
Ca2- influx, that activates Ca2- dependent enzymes and strengthens neuronal synaptic 
association. Besides, diffusible ligands (ADDL) binding to particular synaptic sites and the 
resulting oxidative stress and synapse loss are markedly decreased by the presence of 
insulin. This mechanism is associated with a signal dependent down regulation of ADDL 
binding sites. Low peripheric insulin level may increase cerebral glucose and modulate 
cognitive functions. Besides, low levels of insulin contributes reverse the anamnestic effects 
of cholinergic blockade. 
7. References 
Citron, M. (2002). Alzheimer's disease: treatment in discovery and development. Nat 
Neurosci. 5:1055-7. 
Peila, R.; Rodriguez, BL. & Lauren, LJ. (2002). Type-2 diabetes, diabetes, Apo E gene and the 
risk for dementia and related pathogenesis: the Honolulu-Asia Aging Study. 
Diabetes. 51:1256-62. 
Ott, A.; Stolk, RP.; Hofman, A.; Van Harskamp, F.; Pols, HA. & Breteler MM. (1996). Diabetes 
mellitus and risk of dementia: the Rotterdarm Study. Neurology 53(9);1907-9. 
Luchsinger, JA.; Tang, MX.; Shea, S. & Mayeux, R. (2004). Hyperinsulinemia and risk of 
Alzheimer's disease. Neurology 63:1187-92. 
Janson, J.; Laedtke, T.; Parisi, JE.; O Brien, P.; Petersen, RC. & Butler, PC. (2004). Increased 
risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474-81. 
Whitmer, RA.; Sidney, S.; Selby, J.; Johnston, SC. & Yaffe, K. (2005) Midlife cardiovascular 
risk factors and risk of dementia in late life. Neurology 64:277-81 
Han, W. &  Li, C. (2010) Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci 
USA. 107:6557-8.  
Freude, S.; Schilbach, K & Schubert, M. (2009). The role of IGF-1 receptor and insulin 
receptor signaling for the pathogenesis of Alzheimer's disease: from model 
organism to human disease. Current Alzheimer Research 6:213-23. 
Carro, E. & Torres-Aleman, I. (2004). The role of insulin and insulin-like growth factor I in 
the molecular and cellular mechanisms underlying the pathology of Alzheimer's 
disease. Eur J of Pharmacology 490:127-33. 
Byme, JH. (2003). Learning and memory: basic mechanism. In: Squire LR, Bloom FE, Mc 
Connel SK, Roberts JL, Spitzer NC, Zigmond MJ, editors. Fundamental 
neuroscience. San Diego (CA): Academic Press 1276–98. 
Qiu, WQ. & Folstein, MF. (2006). Insulin, insulin-degrading enzyme and amyloid-beta 
peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27:190-8. 
Fisman, M.; Gordon, B.; Feleki, V.; Helmes, T.; Mac Donald & J, Dupre. (1988). Metabolic 
changes in Alzheimer's disease. J. Am. Geriatr Soc. 36:298-300. 
Plastino, M.; Fava, A.; Pirritano, D.; Cotronei, P.; Sacco, N.; Sperlì, T.; Spanò, A.; Gallo, D.; 
Mungari, P.; Consoli, D &, Bosco, D. (2010). Effects of insulinic therapy on cognitive 
impairment in patients with Alzheimer disease and diabetes mellitus type-2. J 
Neurol Sci 288:112-6.   
Craft, S.; Asthana, S.; Newcomer, JW.; Wilkinson, CW.; Matos, IT.; Baker, LD.; Cherrier, K.; 
Purganan, K.; Wait, C.; Petrova, A.; Plymate, S.; Raskind, M.; Grimwood, K & 
Veith, RC. (1999). Enhancement of Alzheimer disease with insulin and 
somatostatin, but not glucose. Arch Gen Psychiatry 56:1135-40. 
www.intechopen.com
 Glucose Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis   
 
451 
Craft, S.; Asthana, S.; Cook, DG.; Baker, LD.; Cherrier, K.; Purgan, K.; Wait, C.; Petrova, A.; 
Latendresse, S.; Watson, GS.; Newcomer, JW.; Schelleenberg, GD & Kreohn, AJ. 
(2003). Insulin dose-response effects on memory and plasma amyloid precursor 
protein in Alzheimer’s disease: interaction's with Apolipoprotein E genotype. 
Psychoneuroendocrinology 28:809-22. 
Den Heijer, T.; Vermeer, SE.; Van Dijk, EJ.; Prins, ND.; Koudstaal, PJ.; Hofman, A & Breteler, 
MM. (2003). Type 2 diabetes and atrophy of medial temporal lobe structures on 
brain MRI, Diabetologia 46:1604-10. 
Craft, S.; Ashana, G.; Schellenberg, G.; Baker, L.; Cherrier, M.; Boyt, AA.; Martins, RN.; 
Rakind, M.; Peskind, E. & Plymate, S. (2000). Insulin effects on glucose metabolism, 
memory and plasma amyloid precursor protein in Alzheimer’s disease differ 
according to apolipoprotein-E-genotype. Ann NY Acad Sci 903:222-8. 
Messier, C. (2003). Diabetes, Alzheimer's disease and apolipoprotein genotype. Exp Gerontol. 
38:941-6. 
Woods, SC.; Seeley, RJ.; Baskin, DG. & Schwartz, MW. (2003). Insulin and the blood brain 
barrier. Curr Pharm Des. 9:795-800. 
Banks, WA. (2004). The source of cerebral insulin. Eur J Pharmacol. 490:5-12. 
Schechter, R.; Whitmire, J.; Wheet, GS.; Beju, D.; Jackson, KW.; Harlow, R. & Gavin, JR. 
(1994). Immunohistochemical and in situ hybridization study of an insulin-like 
substance in fetal neuron cell cultures. Brain Res. 636:9-27. 
Devaskar, SU.; Giddings, SJ.; Rajakumar, PA.; Carnaghi, LR.; Menon, RK. & Zahm, DS. 
(1994). Insulin gene expression and insulin synthesis in mammalian neuronal cells. 
J Biol Chem. 269:8445-54. 
Havrankova, J.; Schmechel, D.; Roth, J. & Brownstein, M. (1978). Identification of insulin in 
rat brain. Proc Natl Acad Sci USA. 75:5737-41. 
Unger, JW.; Livingston, JN. & Moss, AM. (1991). Insulin receptors in the central nervous 
system: localization, signaling mechanisms and functional aspects. Prog Neurobiol. 
36:343-62. 
Baskin, DG.; Porte, DJ.; Guest, K. & Dorsa, DM. (1983). Regional concentrations of insulin in 
the rat brain. Endocrinology. 112:898-903. 
Johnston, AM.; Pirola, L. & Van Obberghen, E. (2003). Molecular mechanisms of insulin 
receptor substrate protein-mediated modulation of insulin signaling. FEBS Lett. 
546:32-6. 
Kahn, CR.; Bird, KI.; Jarrett, DB. & Flier, JS. (1978). Direct demonstration that receptor cross-
linking or aggregation is important in insulin action. Proc Natl Acad Sci USA. 
75:4209-13. 
Sun, XJ.; Rothenberg, P.; Kahn, CR.; Backer, JM.; Araki, E.; Wilden, PA.; Cahill, DA. 
Goldstein, BJ & White, MF. (1978). Structure of insulin receptor substrate IRS-1 
defines a unique signal transduction protein. Nature 352:73-7. 
Giovannone, B.; Scaldaferri, ML.; Federici, M.; Porzio, O.; Lauro, D.; Fusco, A.; Sbraccia, P.; 
Borboni, P.; Lauro, R. & Sesti, G. (2000). Insulin receptor substrate (IRS) 
transduction system: distinct and overlapping signaling potential. Diabetes Metab 
Res Rev 16:434-41 
Messier, C. & Teutenberg, K. (2005). The role of insulin, insulin growth factor, and insulin-
degrading enzyme in brain aging and Alzheimer's disease. Neural Plast. 12:311-28. 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
452 
Banks, WA.; Jaspan, JB.; Huang, W. & Kastin, AJ. (1997). Transport of insulin across the 
blood-brain barrier to insulin: saturability at euglycemic doses of insulin. Peptides. 
1997; 18: 1423-9. 
Tchilian, EZ.; Zhelezarov, IE.; Patkov, VV. & Hadjiivanova, CI. (1990). 125I-insulin binding 
is decreased in olfactory bulbs of aged rats. Neuropeptides. 17:193-6.  
Adem, A.; Jossan, SS.; D’Argy, R.; Gillberg, PG.; Nordberg, A.; Winblan, B.  & Sara, V. 
(1989). Insulin-like growth factor 1 IGF-1 receptors in the human brain: quantitative 
autoradiographic localization. Brain Res. 503:299-303. 
Chung, YH.; Shin, GM.; Joo, KM & Cha, CI. (2002). Region specific alterations in insulin-like 
growth factor receptor type I in the cerebral cortex and hippocampus of aged rats. 
Brain Res 946:307-13. 
Frolic, L.; Blum-Degen, D.; Berstein, HG.; Engelsberger, S.; Humrich, J.; Laufer, S.; 
Muschner, D.; Thalheimer, A.; Türk, A.; Hoyer, S.; Zöchling, R.; Boissl, KW.; 
Jellinger, K & Riederer, P. (1998). Brain insulin and insulin receptors in aging and 
sporadic Alzheimer s disease. J Neural Transm 105:423-38. 
Banks, WA. & Kastin, AJ. (1985). Peptides and the blood-brain barrier: lipophilicity as a 
predictor of permeability. Brain Res Bull. 15:287-92. 
King, GL. & Johnson, SM. (1987). Receptor-mediated transport of insulin across endothelial 
cells. Science. 227:1583-6. 
Jialal, I.; King, GL.; Buchwald.; S, Kahn, CR. & Crettaz, M. (1984). Processing of insulin by 
bovine endothelial cells in culture. Internalization without degradation. Diabetes. 
33:794-800. 
Rotwein, P.; Burgess, SK.; Milbrandt, JD. & Krause, JE. (1988). Differential expression of 
insulin-like growth factor geneses in rat central nervous system. Proc Natl Acad Sci 
USA. 85:265-9. 
Zhao, M.; Cribbs, DH.; Anderson, AJ.; Cummings, BJ.; Su, JH.; Wasserman, AT. & Cotman, 
CW. (2003). The induction of the TNF alpha death domain signaling pathway in 
Alzheimer’s disease brain. Neurochem Res 28:307-18. 
Baskin, DG.; Stein, LJ.; Iked, H.; Woods, SC.; Porte, DJ & Dorsa, DM. (2005). Genetically 
obese Zucker rats have abnormality low brain insulin content. Life Sci 36:627-33 
Moloney, AM.; Griffin, RJ.; Timmons, S.; O’Connor, R.; Ravid, R. & O’Neill, C. (2010). 
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease 
indicate possible resistance to IGF-1 and insulin signaling. Neurobiol Aging  
31(2):224-43. 
Messier, C & White, NM. (1987). Memory improvement by glucose, fruttose, and two 
glucose analogs: a possible effect peripheral glucose transport. Behav Neural Biol 
48:104-27. 
Craft, S. (2007). Insulin resistance and Alzheimer's disease. Pathogenesis: potential 
mechanisms and implications for treatment. Curr Alzheimer Res. 4(2):147-52. 
Squire, LR. (1986). Mechanisms of memory. Science. 232:1612-9. 
Svensson, J.; Diez, M.; Engel, J.; Wass, C.; Tivesten, A.; Jansson, JO.; Isaksson, O.; Archer, T.; 
Hökfelt, T & Ohlsson, C. (2006). Endocrine, liver-derived IGF-1 is of importance for 
spatial learning and memory in old mice. J. Endocrinol 189:617-27. 
Dik, MG.; Pluijm, SM.; Jonker, C.; Deeg, DJ.; Lomrcky, MZ & Lips, P. (2003). Insulin-like 
growth factor-1 (IGF-1) and cognitive decline in older persons. Neurobiol Aging 
24:573-81.  
www.intechopen.com
 Glucose Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis   
 
453 
Hoyer, S. (2000). Brain glucose and energy metabolism abnormalities in sporadic 
Alzheimer's disease. Causes and consequences: an update. Exp Gerontol. 35:1363-72. 
Blass, JP.; Gibson, GF. & Hoyer, S. (2002). The role of the metabolic lesion in Alzheimer's 
disease. J Alzheimer Dis. 4:225-32.   . 
Beeri, MS.; Schmeidler, J.; Silverman, JM.; Gandy, S.; Wysocki, M.; Hannigan, CM.; Purohit, 
DP.; Lesser, G.; Grossman, HT & Haroutunian, V. (2008). Insulin in combination 
with other diabetes medication is associated with less Alzheimer neuropathology. 
Neurology 71:750-7. 
Craft, S.; Peskind, E.; Schellenberg, G.; Cherrier, M.; Baker, LD.; Newcomer, J.; Plymate, S.; 
Latendresse, S.; Petrova, A.; Raskind, M.; Peskind, E.; Lofgreen, C. & Grimwood, K. 
(1999). Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease differs 
according to apolipoprotein E genotype and gender. Neuroendocrinology. 70:146-52. 
Adamo, M.; Raizada, MK. & LeRoith, D. (1989). Insulin and insulin growth factors receptors 
in the nervous system. Mol Neurobiol. 3:71-100. 
Squire, LR. (1992). Memory and the hippocampus: a synthesis of findings with rats, 
monkeys, and humans. Psychol Rev. 99:195-231. 
Hoyer, S.; Henneberg, N.; Knapp, S.; Lannert, H. & Martin, E. (1996). Brain glucose 
metabolism is controlled by amplification and desensitization of the neuronal 
insulin receptor. Ann NY Acad Sci. 777:374-9.  
Messier, C. & Destrade, C. (1994). Insulin attenuates scopolamine-induced memory deficits. 
Psychobiology. 22:16-21. 
Skeberdis, VA.; Lan, J.; Zheng, X.; Zukin, RS. & Bennett, MV (2001). Insulin promotes rapid 
delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc 
Natl Acad Sci USA. 98:3561–6. 
De Felice, FG.; Vieira, MN.; Bomfirm, TR.; Decker, H.; Velasco, PT.; Lambert, MP.; Viola, 
KL.; Zhao, WQ.; Ferreira, ST. & Klein WL. (2009). Protection of synapses against 
Alzheimer’s linked toxins: insulin signaling prevents the pathogenic binding of A-
beta oligomers. Proc Natl Acad Sci. USA 106:1971-6. 
De la Monte, SM.; Tong, M.; Lester-Coll, N.; Plater M, Jr.; & Wands, JR. (2006). Therapeutic 
rescue of neurodegeneration experimental type-3 diabetes: relevance to 
Alzheimer’s disease. J Alzheimers Dis. 10:89-109. 
Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, RL.; Atwood, CS.; Johnson, AB.; 
Kress, Y.; Vinters, HV.; Tabaton, M.; Shimohama, S.; Cash, AD.; Siedlak, SL.; Harris, 
PL.; Jones, PK.; Petersen, RB.; Perry, G & Smith, MA. (2001). Mitochondrial 
abnormalities in Alzheimer’s disease. J Neurosci 21:3017-23. 
Gouras, GK.; Almeida, CG. & Takahashi, RH. (2005). Intraneuronal Abeta accumulation and 
origin of plaques in Alzheimer’s disease. Neurobiol Aging. 26:1235-44. 
Caspersen, C.; Wang, N.; Yao, J.; Sosunov, A.; Chen, X.; Lustbader, JW.; Xu, HW.; Stern, D.; 
McKhann, G & Yan, SD. (2005). Mitochondrial Abeta: a potential focal point for 
neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J. 19:2040-1. 
Smith, MA.; Perry, G.; Richey, PL.; Sayre, LM.; Anderson, VE.; Beal, MF. & Kowall, N. 
(1996). Oxidative damage in Alzheimer’s disease. Nature 382: 120-1. 
Smith, MA.; Richey Harris, PL.; Sayre, LM.; Beckman, JS. & Perry, G. (1997). Widespread 
peroxynitrite-mediated damage Alzheimer’s disease. J Neurosci. 17:2653-7. 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
454 
Mark, RJ.; Pang, Z.; Geddes, JW.; Uchida, K. & Mattson, MP. (1997). Amyloid-beta peptide 
impairs glucose transport in hippocampal and cortical neurons: involvement lipid 
peroxidation. J Neurosci 17:1046-54. 
Nunomura, A., Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, EK.; Jones, PK.; Ghanbari, 
H.; Wataya, T.; Shimohama.; S.; Chiba, S.; Atwood, CS.; Petersen, RB. & Smith, MA. 
(2001). Oxidative damage is the earliest event in Alzheimer’s disease. J Neuropahol 
Exp Neurol 60:759-67. 
Cho, DH.; Nakamura, T.; Fang, J.; Cieplak, P.; Godzik, A.; Gu, Z. & Lipton, SA. (2009). S-
nitrosylation of Drp l mediates beta-amyloid-related mithocondrial fissation and 
neuronal injury. Science. 324:102-5. 
Yan, SD.; Chen, M.; Zhu, H.; Roher, A.; Slattery, T.; Zhao, L.; Nagashima, M.; Morser, J.; 
Migheli, A.  Nawroth P, Stern, D. & Schmidt, AM. (1996). RAGE and amyloid-beta 
peptide neurotoxicity in Alzheimer’s disease. Nature 382:685-91. 
Lue, LF.; Walker, DG.; Jacobson, S. & Sabbagh, M. (2009). Receptor for advanced glycation 
end products: its role in Alzheimer’s disease and other neurological diseases. Future 
Neurol. 4:167–77. 
Cho, HJ.; Son, SM.; Jin, SM.; Hong, HS.; Shin, DH.; Kim, SJ.; Huh, K. & Mook-Jung, I. (2009). 
RAGE regulates BACE1 and A-beta generation via NFAT1 activation in 
Alzheimer’s disease animal model. FASEB J 23:2639–49. 
Martin, SJ.; Grimwood, PD. & Morris, RG. (2000). Synaptic plasticity and memory: an 
evaluation of the hypothesis. Annu Rev Neurosci. 23:649-711. 
Ding, Q. & Keller, JN. (2005). Splice variants of the receptor for advanced glycosylation end 
products (RAGE) in human brain. Neurosci Lett. 373:67–72. 
Raucci, A.; Cugusi, S.; Antonelli, A.; Barabino, SM.; Monti, L.; Bierhaus, A.; Reiss, K.; Saftig, 
P. & Bianchi, ME. (2008). A soluble form of the receptor for advanced glycation 
endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound 
form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 
22:3716–27. 
Lue, LF.; Walker, DG.; Brachova, L.; , Beach, TG.; Rogers, J.; Schmidt, AM.; Stern, DM. & 
Yan, SD. (2001). Involvement of microglial receptor for advanced glycation 
endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation 
mechanism. Exp Neurol. 171:29–45. 
Deane, R.; Du Yan, S.; Submamaryan, RK.; LaRue, B.; Jovanovic, S.; Hogg, E.; Welch, D.; 
Manness, L.; Lin, C.; Yu, J.; Zhu, H.; Ghiso, J.; Frangione, B.; Stern, A.; Schmidt, 
AM.; Armstrong, DL.; Arnold, B.; Liliensiek, B.; Nawroth, P.; Hofman, F.; Kindy, 
M.; Stern, D. & Zlokovic, B..(2003). RAGE mediates amyloid-beta peptide transport 
across the blood–brain barrier and accumulation in brain. Nat Med. 9:907–13. 
Emanuele, E.; D’angelo, A.; Tomaino, C.; Binetti, G.; Ghidoni, R.; Politi, P.; Bernardi, L.; 
Maletta, R.; Bruni, AC. & Geroldi, D. (2005). Circulating levels of soluble receptor 
for advanced glycation end products in Alzheimer disease and vascular dementia. 
Arch Neurol. 62: 1734–6. 
Lee, VM.; Goedert, M. & Trojanowski, JQ. (2001). Neurodegenerative tauopathies. Ann Rev 
Neurosci. 24:1121-59. 
Iqbal, K.; Alonso Adel, C.; Chen, S.; Chohan, MO.; El-Akkad, E.; Gong, CX.; Khatoon, S.; Li, 
B.; Liu, F.; Rahman, A.; Tanimukai, H. & Grundke-Iqbal, I.  (2005).Tau pathology in 
Alzheimer’s disease and other tauopathies. Biochim Biophys Acta 1793:198-210. 
www.intechopen.com
 Glucose Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis   
 
455 
Delacourte, A.; Sergeant, N.; Champain, D.;  Wattez, A.; Maurage, CA.; Lebert, F.; Pasquier, 
F. & David, JP. (2002). Nonoverlapping but synergetic tau and APP pathologies in 
sporadic Alzheimer’s disease. Neurology 59:398-407. 
Glenner, GG. & Wong, CW. (1984). Alzheimer disease: initial report of the purification and 
characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res 
Commun 120:885-90. 
Flaherty, DB.; Soria, JP.; Tomasiewicz, HZ. & Wood, JG. (2000). Phosphorylation of human 
tau protein by microtubule associated kinases: GSK3┚ and cdk5 are key 
partecipants. J Neurosci Res 62:463-72. 
Stoothoff, WH. & Johnson, GV. (2005). Tau phosphorylation: physiological and pathological 
consequences. Biochim Biophys Acta 1739:280-97. 
Millward, TA.; Zolnierowicz, S. & Hemmings, BA. (1999). Regulation of protein kinase 
cascades by protein phosphatase 2A. Trends Biochem Sci. 24:186-91. 
Doble, BW. & Woodgett, JR. (2003). GSK-3┚: tricks of the trade for a multi-tasking kinase. J 
Cell Sci 116:1175-86. 
Avila J. (2008). Tau kinases, phosphatases. J Cell Mol Med. 12:258-9. 
Liu, R.; Zhou, XW.; Tanila, H.; Bjorkdahl, C., Wang, JZ.; Guan, ZZ.; Cao, Y.; Gustafsson, JA.; 
Winblad, B. & Pei, JJ. (2008). Phosphorylated PP2A (tyrosine 307) is associated with 
Alzheimer neurofibrillary pathology. J Cell Mol Med 12:241-57. 
Hong, M. & Leev, VM. (1997). Insulin and insulin-like growth factor-1 regulate tau 
phosphorylation in cultured human neurons. J. Biol. Chem 272:19547-53. 
Meske, V.; Albert, F. & Ohm, TG. (2008). Coupling of mammalian target of rapamyein with 
phosphoinositide 3-kinase signaling pathway regulates protein phospatase 2A and 
glycogen synthase kinase-3-dependent phosphorylation of tau. J. Biol Chem 283:100-
9.  
Cheng, CM.; Tseng, V.; Wang, J.; Wang, D.; Matyakhina, L. & Bondy, CA. (2005). Tau is 
hyperphosporylated in the insulin-like growth factor-I null brain. Endocrinology 
146:5086-91.   
Schubert, M.; Brazil, DP.; Burks, DJ.; Kushner, JA.; Ye, J.; Flint, CL.; Farhang-Fallah, J.; 
Dikkes, P.; Warot, XM.; Rio, C.; Corfas, G. & White, MF. (2003). Insulin receptor 
substrate-2 deficiency impairs brain growth and promotes tau phosporylation. J 
Neurosc. 23:7084-92. 
Planel, E.; Tatebayashi, Y.; Miyasaka, T.; Liu, L.; Wang, L.; Herman, M.; Yu, WH.; 
Luchsinger, JA.; Wadzinski, B.; Duff, KE. & Takashima, A. (1997).Insulin 
dysfunction induces in vivo tau after hyperphosphorylation through distinct 
mechanisms. J Neurosci 27:13635-48. 
Kolch, W. (2000). Meaningful relationships: the regulation of the RAS/RAF/MEK/ERK 
pathway by protein interactions. Biochem J 351: 289-305. 
Sweatt, JD. (2001). The neuronal MAP kinase cascade: a biochemical signal integration 
system subserving synaptic plasticity and memory. J Neurochem 76:1-10 
Zhuang, S. & Schnellmann, RG. (2006). A death-promoting role for extracellular signal-
regulated kinase. J Pharmacol Exp Ther 319:991-7. 
Lesort, M & Johnson, GV. (2000). Insulin-like growth factor-1 and insulin mediate transient 
site-selective increases in tau phosphorylation in primary cortical neurons. 
Neuroscience. 99:305–16. 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
456 
Kang, J.; Lemaire, HG.; Unterbeck, A.; Salbaum, JM.; Masters, CL.; Grzeschik, KH.; 
Multhaup, G.; Beyreuther, K. & Müller-Hill, B. (1987). The precursor of Alzheimer-s 
disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-6. 
Zhang, Y.; Thompson, R.; Zhang, H. & Xu, U. (2011). APP processing in Alzheimer’s disease. 
Mol Brain. 4: 3. 
Kimberly, WT.; LaVoie, MJ.; Ostaszewski, BL; Ye, W.; Wolfe, MS. & Selkoe DJ. (2003). 
Gamma-secretase is a membrane protein complex comprised of presenilin, 
nicastrin, Aph-1 and Pen-2. Proc Natl Acad Sci USA. 100: 6382-7. 
Vassar, R.; Bennett, BD.; Babu-Kahn, S.; Kahn, S.; Mendiaz, EA.; Denis, P.; Teplow, DB.; 
Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; 
Jarosinski, MA.; Biere, AL.; Curran, E.; Burgess, T.; Louis, JC.; Collins, F.; Treanor, 
J.; Rogers, G. & Citron, M. (1999). Beta-secretase cleavage of Alzheimer’s amyloid 
precursor protein by the transmembrane aspartic protease BACE. Science. 286:735-
41. 
Holsinger, RM.; McLean, CA.; Beyreuther, K.; Masters, CL, & Evin, G (2002). Increased 
expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann 
Neurol. 51:783-6. 
Costantini, C.; Scrable, H. & Puglielli, L. (2006). An aging pathway controls the TrkA to 
p75NTR receptor switch and amyloid beta-peptide generation. EMBO J 25:1997-
2006. 
Puglielli, L. (2008). Aging of the brain, neurotrophic signaling, and Alzheimer’s disease: is 
IGF-1R the common culprit? Neurobiol Aging. 29:795-811. 
Puglielli, L.; Ellis, BC.; Saunders, AJ. & Kovacs, DM. (2003). Ceramide stabilizes beta-size 
amyloid precursor protein-cleaving enzyme I and promotes amyloid beta-peptide 
biogenesic. J Biol Chem. 278:19777-83. 
Kayed, RH.; Thompson. JL.; MC Intire, TM.; Milton, SC.; Cotman, CW. & Glabe, CG. (2003). 
Common structure of soluble amyloid oligomers implies common mechanism of 
pathogenesis. Science 300:486-9. 
Hass, C. & Sedkoe, DJ. (2007). Soluble protein oligomers in neuro-degeneration: lessons 
from the Alzheimer’s amyloid beta-peptide. Nat Rev Mol Cell Bio. 8:101-2. 
Kamenetz, F.; Tomita, T.; Hsieh, H.; Seabrook, G.; Borchelt, D.; Iwatsubo, T.; Sisodia, S. & 
Malinow, R. (2003). APP Processing and synaptic function. Neuron. 37:925-37. 
Tanzi, RE.; Moir, RD. & Wagner, SL. (2005). Twenty years of the Alzheimer disease amyloid 
hypothesis: a genetic perspective. Cell. 120:545-55. 
Selkoe, DJ. (1999). Translating cell biology in to therapeutic advances in Alzheimer’s disease. 
Nature. 399:23-31. 
Cheng, S.; Li, L.; He, S.; Liu, J.; Sun, Y.; He, M.; Grasing, K.; Premont, RT.  & Suo, WZ. (2010). 
GRK5 deficiency accelerates ß-amyloid accumulation in Tg2576 mice via impaired 
cholinergic activity. J Biol Chem. 285:41541-8. 
Carro, E.; Trejo, JL.; Spuch, C.; Heard, JM. & Torres-Aleman, I.  (2006). Blockade of the 
insulin-like growth factor I receptor in the choroid plexus originates Alzheimer’s 
like neuropathology in rodents; new cues into the human disease? Neurobiol Aging 
27:1618-31. 
Suh, Y.; Atzomon, G.; Cho, Mo.; Hwang, D.; Liu, B.; Leahy, DJ.; Barzilai, N. & Cohen, P. 
(2008). Functionally significant insulin-like growth factor I receptor mutations in 
centenarians. Proc Natl Acad Sci USA. 105:3438-42.   
www.intechopen.com
 Glucose Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis   
 
457 
Ho, L.; Qin, W.; Pompl, PN.; Xiang, Z; Wang, J.; Zhao, Z.; Peng, Y.; Cambareri, G.; Rocher, 
A.; Mobbs, CV.; Hof, PR. & Pasinetti, GM. (2004). Diet-induced insulin resistance 
promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB 
J 18:902-4. 
Cao, D.; Lu, H.; Lewis, TI. & Li, L. (2007). Intake of sucrose-sweetened water induced insulin 
resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse 
model of Alzheimer disease. J Biol Chem. 282:36275-82. 
Freude, S.; Plum, L.; Schnitker, J.; Leeser, U.; Udelhoven, M.; Krone, W.; Bruning, JC. & 
Schubert, M. (2005). Peripheral hyperinsulinemia promotes tau phosphorylation in 
vivo. Diabetes 54:3343-8. 
Takeda, S.; Sato, N.; Uchio-Yamada, K.; Sawada, K.; Kunieda, T.; Takeuchi, D.; Kurinami, H.; 
Shinohara, M.; Rakugi, H. & Morishita, R. (2010). Diabetes accelerated memory 
dysfunction via cerebrovascular inflammation A┚ deposition in Alzheimer mouse 
model with diabetes. Proc Natl Acad Sci USA 107:7036-41 
Montine, TJ.; Kaye, JA.; Montine, KS.; McFarland, L.; Morrow, JD. & Quinn, JF. (2001). 
Cerebrospinal fluid abeta-42, tau, and f2-isoprostane concentrations in patients 
with Alzheimer disease, other dementias, and age-matched controls. Arch Pathol 
Lab Med 125:510-2. 
Sheng, JG.; Bora, SH.; Xu, G.; Borchelt, DR.; Price, DL. & Koliatsos, VE. (2003). 
Lipopolysaccharide-induced-neuroinflammation increase intracellular 
accumulation of amyloid precursor protein and amyloid beta peptide in APPswe 
transgenic mice. Neurobiol Dis 14:133-45. 
Dandona, P. (2002). Endothelium, inflammation and diabetes Curr Diab Rep. 2:311-5. 
Krogh-Madsen, R.; Plomgaard, P.; Keller, P.; Keller, C. & Pedersen BK. (2004). Insulin 
stimulates interlukin-6 and tumor necrosis factor-alpha gene expression in human 
subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 286:234-8. 
Soop, M.; Duxubury, H.; Agwunobi, AO.; Gibson, JM.; Hopkins, SJ.; Childs, C.; Cooper, RG.; 
Maycock, P.; Little, RA. & Carlson, GL. (2002). Euglycemic hyperinsulinemia 
augments the cytokine and endocrine responses in endotoxin in humans. Am J 
Physiol Endocrinol Metab 282:1276-85. 
Zhao, M.; Cribbs, DH.; Anderson, AJ.; Cummings, BJ.; Su, JH.; Wasserman, AT. & Cotman, 
CW. (2003). The induction of the TNF alpha death domain signaling pathway in 
Alzheimer’s disease brain. Neurochem Res 28:307-18. 
Dzienis-Straczkowski, M.; Szelachowska, M.; Stepien, A.; Kowalska, I. & Kinalska, I. (2003). 
Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal 
and impaired glucose tolerance. Diabetes Care 26:875-80. 
Bastard, JP.; Jardel, C.; Bruckert, E.; Vidal, H. & Hainque, B. (2000). Variations in plasma 
soluble tumor necrosis factor receptors after diet-induced weight loss in obesity. 
Diabetes Obes Metab 2:323-5. 
Axelrod, L. (1991). Insulin, prostaglandins, and the pathogenesis of hypertension. Diabetes. 
40:1223-7. 
Facchini, FS.; Hua, NW.; Reaven, GM. & Stoohs, RA. (2000). Hyperinsulinemia: the missing 
link among oxidative stress and age-related disease? Free Radic Biol Med 29:1302-6. 
Mrak, RE. & Griffin, WS. (2001). Interleukin-1, neuroinflammation, and Alzheimer’s disease.  
Neurobiol Aging. 22:903-8. 
www.intechopen.com
  
Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 
 
458 
White, JA.; Manelli, AM.; Holmberg, KH.; Van Eldik,  LJ. & Ladu, MJ. (2005). Differential 
effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte mediated 
inflammation. Neurobiol Dis 18:459-65. 
Papassotiropoulos, A.; Hock, C. & Nitsch, RM. (2001). Genetics of interleukin 6: implications 
for Alzheimer’s disease. Neurobiol Aging. 22:863-71. 
Descamps, O.; Bilheimer, D. & Herz, J. (1993). Insulin stimulates receptor-mediated uptake 
of Apo E-enriched lipoproteins and activated alpha 2-macroglobulin in adypocytes. 
J Biol Chem. 268:974-81. 
Fishel, MA,.; Watson, GS.; Montine, TJ.; Wang, Q.; Green, PS. & Kulstad, JJ. (2005). 
Hyperinsulinemia provokes synchronous increases in central inflammation and 
beta-amyloid in normal adults. Arch Neurol 62:1539-44. 
Yamada, T.; Kondo, A.; Takamatsu, J.; Tateishi, J. & Goto I (1995). Apolipoprotein E mRNA 
in the brains of patients with Alzheimer’s disease. J Neurol Sci. 129:56-61. 
Figlewicz, DP.; Bentson, K. & Octrant I. (1993). The effect of insulin on norepinephrine 
uptake by PC12 cells. Brain Res 602:161-4. 
Heneka, MT.; Galea, E.; Gavriluyk, V.; Dumitrescu-Ozimek, L.; Daeschner, J.; O’Banion, 
MK.; Weinberg, G.; Klockgether, T. & Feinstein, DL. (2002). Noradrenergic 
depletion potentiates beta-amyloid-induced cortical inflammation: implications for 
Alzheimer’s disease. J Neurosci 22:2434-42. 
Bondareff, W.; Mountjoy, CQ.; Roth, M.; Rossor, MN.; Iversen, LL.; Reynolds, GP. & Hauser, 
DL. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer 
disease. Alzheimer Dia Assoc Disord 1987; 1:256-62. 
Watson, GS.; Bernhardt, T.; Reger, MA.; Cholerton, BA.; Baker, LD. & Peskind, ER. (2006). 
Insulin effects on CSF norepinephrine and cognition in Alzheimer’s disease. 
Neurobiol Aging 27:38-41. 
Bingham, EM.; Hopkins, D.; Smith, D.; Pernet, A.; Hallett, W. & Reed, L.  (2002). The role of 
insulin in human brain glucose metabolism: an 18fluoro-deoxyglucose positron 
emission tomography study. Diabetes 51:3384–90.  
Blanchard, JG. & Duncan, PM. (1997). Effect in combinations of insulin, glucose and 
scopolamine on radial arm maze performance. Pharmacol Biochem Behav 58:209–14. 
www.intechopen.com
Alzheimer's Disease Pathogenesis-Core Concepts, Shifting
Paradigms and Therapeutic Targets
Edited by Dr. Suzanne De La Monte
ISBN 978-953-307-690-4
Hard cover, 686 pages
Publisher InTech
Published online 12, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Alzheimer's Disease Pathogenesis: Core Concepts, Shifting Paradigms, and Therapeutic Targets, delivers the
concepts embodied within its title. This exciting book presents the full array of theories about the causes of
Alzheimer's, including fresh concepts that have gained ground among both professionals and the lay public.
Acknowledged experts provide highly informative yet critical reviews of the factors that most likely contribute to
Alzheimer's, including genetics, metabolic deficiencies, oxidative stress, and possibly environmental
exposures. Evidence that Alzheimer's resembles a brain form of diabetes is discussed from different
perspectives, ranging from disease mechanisms to therapeutics. This book is further energized by discussions
of how neurotransmitter deficits, neuro-inflammation, and oxidative stress impair neuronal plasticity and
contribute to Alzheimer's neurodegeneration. The diversity of topics presented in just the right depth will
interest clinicians and researchers alike. This book inspires confidence that effective treatments could be
developed based upon the expanding list of potential therapeutic targets.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Domenico Bosco, Massimiliano Plastino, Antonio Spano ̀, Caterina Ermio and Antonietta Fava (2011). Glucose
Metabolism and Insulin Action in Alzheimer’s Disease Pathogenesis, Alzheimer's Disease Pathogenesis-Core
Concepts, Shifting Paradigms and Therapeutic Targets, Dr. Suzanne De La Monte (Ed.), ISBN: 978-953-307-
690-4, InTech, Available from: http://www.intechopen.com/books/alzheimer-s-disease-pathogenesis-core-
concepts-shifting-paradigms-and-therapeutic-targets/glucose-metabolism-and-insulin-action-in-alzheimer-s-
disease-pathogenesis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
